MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
3.220
+0.060
+1.90%
Closed 19:54 02/09 EST
OPEN
3.190
PREV CLOSE
3.160
HIGH
3.220
LOW
3.055
VOLUME
3.27M
TURNOVER
0
52 WEEK HIGH
6.52
52 WEEK LOW
1.891
MARKET CAP
963.86M
P/E (TTM)
-5.5864
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABCL last week (0202-0206)?
Weekly Report · 1d ago
Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions?
Simply Wall St · 4d ago
OpenAI considers backing AI-led drug discovery firms: report
Seeking Alpha · 6d ago
Weekly Report: what happened at ABCL last week (0126-0130)?
Weekly Report · 02/02 09:09
AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets
Simply Wall St · 01/30 08:38
Weekly Report: what happened at ABCL last week (0119-0123)?
Weekly Report · 01/26 09:09
Advancing Non-Hormonal Menopause Drug Into Phase 2 Could Be A Game Changer For AbCellera (ABCL)
Simply Wall St · 01/24 09:30
Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
Dow Jones · 01/23 00:10
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.